Trial Profile

A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapuleucel T (Primary)
Indications Urogenital cancer
Focus Therapeutic Use
Acronyms Neu-ACT
Sponsors Dendreon Corporation

Most Recent Events

21 Apr 2017 Status changed from completed to discontinued due to administrative reasons
07 Jun 2016 Primary endpoint (overall survival rate) has not been met, according to a results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com